Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Pediatr Nephrol. 2023 May 5;38(10):3465–3474. doi: 10.1007/s00467-023-05997-9

Table 3b:

Univariate analysis of continuous variables

Covariate AKD (n=297) No AKD (n=231) Difference in means 95% CI P-value
Age at AKI diagnosis (months) 45.8 45.3 −0.5 −10.9 – 9.8 0.923
BMI (kg/m2) 15.4 15.7 0.3 −0.8 – 1.4 0.574
AKI duration (days) 6.1 4.5 −1.5 −1.9 – −1.2 <0.001
Total number of nephrotoxic medication exposures in AKI period 8.7 exposures 7.2 exposures −1.4 −2.8 – −0.1 0.034
Number of contrast studies in AKI period 0.2 studies 0.3 studies 0.1 −0.03 – 0.2 0.167